Equity: Global Genomic Advancements
With 4 ETFs and over $7.79B in combined AUM, the Equity: Global Genomic Advancements segment provides exposure to the Global space with a focus on Theme securities.
Year-to-date, the best-performing ETF in the segment is the Franklin Genomic Advancements ETF (HELX), with a total return of 10.88%. Meanwhile, the most popular ETF is the ARK Genomic Revolution ETF (ARKG) with $7.15BB in assets under management.
Investors should take a look at the (). This fund has been chosen as an Analyst Pick by FactSet, thus is the best ETF for the average investor. has an expense ratio of -- and tracks the .
ETF.com Efficiency Insight
The average efficiency score in the Equity: Global Genomic Advancements segment is 80 out of 100, with the Franklin Genomic Advancements ETF(HELX) obtaining the highest rating of 81 out of 100.
Costs dominate the discussion around efficiency. ETFs in the segment have an average expense ratio of 0.56% per year, with the iShares Genomics Immunology and Healthcare ETF (IDNA) having the lowest expense ratio, charging investors 0.47% yearly.
Investors should look for funds with tight tracking, such as the Global X Genomics & Biotechnology ETF (GNOM), with a 12-month median tracking difference of --.
ETF.com Tradability Insight
The average tradability score in the Equity: Global Genomic Advancements segment is 85 out of 100, with the ARK Genomic Revolution ETF(ARKG) obtaining the highest rating of 96 out of 100.
The ARK Genomic Revolution ETF (ARKG) is the undisputed segment leader when it comes to liquidity. The fund trades 147.00M in daily average volume. Investors should also find ample liquidity in the iShares Genomics Immunology and Healthcare ETF (IDNA), with $2.88M in daily dollar volume.
Use limit orders to trade funds such as the Franklin Genomic Advancements ETF(HELX), due to their double-digit market spreads.
ETF.com Fit Insight
The has been selected as the index that most accurately represents the market in question. The benchmark has been selected by the ETF Analytics team at FactSet, according to a series of guidelines to ensure this index accurately captures its market.
Investors trying to match a broad market exposure should pay attention to . This fund obtains a high Fit score and investors should capture market-like returns.
Other funds diverge from the market, by nature of their investment mandates; for example, follows a strategy and obtains a low Fit score compared with our neutral benchmark.